Literature DB >> 2175673

Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.

E W Nijhuis1, E vd Wiel-van Kemenade, C G Figdor, R A van Lier.   

Abstract

Cytotoxic T lymphocytes from healthy donors can be expanded to high numbers from the peripheral blood using combinations of anti-CD3 and anti-CD28 monoclonal antibodies (mAb). We investigated whether these antibodies could also be used to induce outgrowth of tumour-infiltrating lymphocytes (TIL) from tumour tissue. In the initiation phase of TIL culture immobilized anti-CD3 antibodies together with anti-CD28 mAb and low-dose interleukin-2 induced a rapid expansion of T cells from various human tumour tissues. The cultured cells showed high levels of cytotoxic T lymphocyte activity, but low levels of lymphokine-activated killer cell activity were generated. This study shows that TIL can be efficiently expanded from tumour tissue by combinations of anti-CD3 and anti-CD28 antibodies. This protocol for cell expansion in vitro may substantially reduce the time required to reach sufficient numbers of TIl for re-infusion to the patient.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2175673     DOI: 10.1007/BF01741708

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  26 in total

1.  Synergy between the T3/antigen receptor complex and Tp44 in the activation of human T cells.

Authors:  A Weiss; B Manger; J Imboden
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

2.  Selective changes in expression of HLA class I polymorphic determinants in human solid tumors.

Authors:  P G Natali; M R Nicotra; A Bigotti; I Venturo; L Marcenaro; P Giacomini; C Russo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  T90/44 (9.3 antigen). A cell surface molecule with a function in human T cell activation.

Authors:  W Lesslauer; F Koning; T Ottenhoff; M Giphart; E Goulmy; J J van Rood
Journal:  Eur J Immunol       Date:  1986-10       Impact factor: 5.532

4.  Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibody.

Authors:  D D Schoof; S E Jung; T J Eberlein
Journal:  Int J Cancer       Date:  1989-08-15       Impact factor: 7.396

5.  In vitro activation of lymphocytes from nonsmall cell cancer patients by interleukin 2 and anti-CD3 antibody.

Authors:  R J Pisani; P J Leibson; D J McKean
Journal:  Clin Immunol Immunopathol       Date:  1989-03

6.  Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3.

Authors:  T D Geppert; P E Lipsky
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

7.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

8.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

9.  Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies.

Authors:  R A Van Lier; M Brouwer; L A Aarden
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  14 in total

1.  HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas.

Authors:  J J Bijl; E Rieger; J W van Oostveen; J M Walboomers; M Kreike; R Willemze; C J Meijer
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.

Authors:  C D Rice; N G Baldwin; R T Biron; H D Bear; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

Review 3.  Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.

Authors:  Richard D Lopez
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies.

Authors:  M J Flens; W M Mulder; H Bril; M B von Blomberg van de Flier; R J Scheper; R A van Lier
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

5.  Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.

Authors:  Catriona H T Miller; Laura Graham; Harry D Bear
Journal:  BMC Immunol       Date:  2010-11-04       Impact factor: 3.615

6.  Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.

Authors:  L T Vlasveld; E van de Wiel-van Kemenade; A J de Boer; J J Sein; M P Gallee; R T Krediet; C J Mellief; E M Rankin; A Hekman; C G Figdor
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

7.  Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.

Authors:  J Koberda; E A Grimm; R P Moser
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.

Authors:  Esther Cha; Laura Graham; Masoud H Manjili; Harry D Bear
Journal:  Breast Cancer Res Treat       Date:  2009-10-14       Impact factor: 4.872

9.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

Review 10.  Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

Authors:  P M Anderson; M A Sorenson
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.